Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

      This image opens in the lightbox

      News provided by

      Alkermes plc

      13 Feb, 2020, 12:00 GMT

      Share this article

      Share this article


      —  Revenues of $1.17 Billion in 2019, Driven by Year-Over-Year Growth of Proprietary Product Net Sales and VUMERITY® Milestone Payment —

      —  2019 GAAP Net Loss per Share of $1.25 and Diluted Non-GAAP Earnings per Share of $0.71 —

      —  Financial Expectations for 2020 Reflect Growth of Proprietary Products and Impact of Strategic Restructuring —

      DUBLIN, Feb. 13, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.

      "2019 was an important year for Alkermes as we took active steps to shape the future of our business and continued to make a real-world impact in the treatment of serious diseases. We made significant progress on three fronts: driving growth in our proprietary product portfolio, advancing and expanding our diversified neuroscience and oncology pipeline, and positioning the business for long-term growth and future profitability," said Richard Pops, Chief Executive Officer of Alkermes. "Looking ahead, our priorities for 2020 are clear as we focus on commercial execution for VIVITROL® and ARISTADA®, prepare for potential approval and launch of ALKS 3831, advance the development of ALKS 4230, and continue to develop our pipeline of preclinical assets. We remain steadfast in our commitment to be a positive force for change through our science, our medicines, and our advocacy, as we advance patient-centered care."

      Quarter Ended Dec. 31, 2019 Financial Highlights

      • Total revenues for the quarter were $412.7 million. This compared to $315.8 million for the same period in the prior year.
      • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $5.4 million for the quarter, or a basic and diluted GAAP loss per share of $0.03. This compared to GAAP net loss of $9.7 million, or a basic and diluted GAAP loss per share of $0.06, for the same period in the prior year.
      • Non-GAAP net income was $131.4 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.83. This compared to non-GAAP net income of $54.8 million, or a non-GAAP basic earnings per share of $0.35 and non-GAAP diluted earnings per share of $0.34, for the same period in the prior year.
      • In October 2019, Alkermes implemented a strategic restructuring plan, which included the elimination of approximately 160 current positions across the organization, a decrease in the company's expected near-term hiring plans and the implementation of cost-saving measures related to external spend. These efforts are expected to result in cost savings of approximately $150 million in 2020.
      • In November 2019, Alkermes completed the acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. At the closing of the transaction, Alkermes made a cash payment of $98.1 million to Rodin's former security holders. This upfront cash payment was funded by Alkermes' available cash and was accounted for as an asset acquisition, with $86.6 million of this upfront payment recorded as research and development (R&D) expense in the quarter.

      Quarter Ended Dec. 31, 2019 Financial Results

      Revenues

      • Net sales of proprietary products were $149.6 million, compared to $132.7 million for the same period in the prior year.
        • Net sales of VIVITROL were $92.8 million, compared to $83.8 million for the same period in the prior year, representing an increase of approximately 11%.
        • Net sales of ARISTADAi were $56.8 million, compared to $48.8 million for the same period in the prior year, representing an increase of approximately 16%.
      • Manufacturing and royalty revenues were $107.3 million, compared to $167.4 million for the same period in the prior year.
        • Manufacturing and royalty revenues from RISPERDAL CONSTA®, INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA®/TREVICTA® were $79.1 million, compared to $81.4 million for the same period in the prior year.
        • Manufacturing and royalty revenues from AMPYRA/FAMPYRA®ii were $7.5 million, compared to $38.8 million for the same period in the prior year, due to generic competition to AMPYRA entering the U.S. market in 2018.
        • Manufacturing and royalty revenues in the fourth quarter of 2018 included $26.7 million related to Alkermes' share of proceeds from the sale of certain royalty streams by Zealand Pharma A/S related to products using Alkermes technology.
      • Total revenues also included a $150.0 million milestone payment from Biogen related to the U.S. Food and Drug Administration (FDA) approval of VUMERITY, of which $144.8 million was recorded as license revenue and $5.2 million was recorded as R&D revenue.
      • R&D revenues were $11.1 million, primarily related to R&D reimbursement from the company's collaboration with Biogen for VUMERITY and a portion of the milestone payment noted above.

      Costs and Expenses

      • Total operating expenses were $422.7 million, compared to $315.7 million for the same period in the prior year.
        • R&D expenses were $198.2 million, which included $86.6 million related to the acquisition of Rodin during the fourth quarter. Excluding this R&D charge related to Rodin, R&D expenses were $111.6 million compared to $109.0 million for the same period in the prior year.
        • Selling, General and Administrative (SG&A) expenses were $154.5 million, compared to $141.2 million for the same period in the prior year, primarily reflecting increased investment in the commercialization of ARISTADA and VIVITROL.
        • As a result of the restructuring implemented in October 2019, the company recorded a restructuring expense charge of $13.4 million in the fourth quarter of 2019, consisting of one-time termination benefits for employee severance, benefits and related costs.

      "Our 2019 results reflect volume growth of VIVITROL and ARISTADA, continued strength of our royalty and manufacturing portfolio and investment in the commercialization of our products and our research and development pipeline," commented James Frates, Chief Financial Officer of Alkermes. "We enter 2020 well positioned to drive growth of our proprietary product portfolio and advance our pipeline of novel oncology and neuroscience candidates. Our financial expectations for 2020 reflect anticipated net sales growth of our proprietary products and operating expenses in line with the predicted impact of the strategic restructuring that we implemented in the fourth quarter of 2019, reflecting our commitment to non-GAAP profitability while investing in the long-term growth of the company."

      Calendar Year 2019 Financial Highlights

      • Total revenues increased 7% to $1.17 billion in 2019, which included VIVITROL net sales of $335.4 million, ARISTADA net sales of $189.1 million, and the $150.0 million milestone payment from Biogen related to the approval of VUMERITY. This compared to total revenues of $1.09 billion in 2018, which included VIVITROL net sales of $302.6 million, ARISTADA net sales of $147.7 million and license revenues of $48.4 million from Biogen. Please see the tables at the end of this press release for a detailed breakdown of the revenues from our key commercial products.
      • GAAP net loss was $196.6 million, or a basic and diluted GAAP loss per share of $1.25, for 2019. This compared to a GAAP net loss of $139.3 million, or a basic and diluted GAAP loss per share of $0.90, for 2018.
      • Non-GAAP net income was $112.2 million, or a non-GAAP basic and diluted earnings per share of $0.71, for 2019, and excludes the impact of the acquisition of Rodin and the restructuring. This compared to non-GAAP net income of $97.8 million, or a non-GAAP basic earnings per share of $0.63 and non-GAAP diluted earnings per share of $0.61, for 2018.
      • At Dec. 31, 2019, Alkermes recorded cash, cash equivalents and total investments of $614.4 million, compared to $620.0 million at Dec. 31, 2018. At Dec. 31, 2019, the company's total debt outstanding was $277.1 million, compared to $279.3 million at Dec. 31, 2018.

      Recent Events:

      • ALKS 3831
        • In January 2020, the FDA accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar I disorder, and assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020.
      • VUMERITY
        • In October 2019, the FDA approved VUMERITY, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive worldwide license to commercialize VUMERITY. In November 2019, Alkermes received a $150 million milestone payment from Biogen related to the approval of VUMERITY.
      • ALKS 4230
        • In November 2019, Alkermes presented preliminary clinical data from the ARTISTRY-1 phase 1/2 study investigating intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in adults with advanced solid tumors, and study design details and preliminary safety data from the ARTISTRY-2 phase 1/2 study evaluating subcutaneous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
      • HDAC-Inhibitor Platform
        • In November 2019, Alkermes announced the acquisition of Rodin, a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies, which expanded Alkermes' neuroscience development efforts into a wide range of neurodegenerative disorders.

      Financial Expectations for 2020

      The following outlines the company's financial expectations for 2020, which reflect the expected impact of the strategic restructuring implemented in 2019. All line items are according to GAAP, except as otherwise noted.

      • Revenues: The company expects total revenues to range from $1.03 billion to $1.08 billion. Excluding license and R&D revenues from Biogen of approximately $195 million related to the development and approval of VUMERITY recorded in 2019, this represents revenue growth of approximately 8%. Included in this total revenue expectation, Alkermes expects VIVITROL net sales to range from $340 million to $355 million, and ARISTADA net sales to range from $220 million to $235 million.
      • Cost of Goods Manufactured and Sold: The company expects cost of goods manufactured and sold to range from $185 million to $195 million.
      • Research and Development (R&D) Expenses: The company expects R&D expenses to range from $405 million to $430 million.
      • Selling, General and Administrative (SG&A) Expenses: The company expects SG&A expenses to range from $535 million to $560 million.
      • Amortization of Intangible Assets: The company expects amortization of intangibles to be approximately $40 million.
      • Net Interest Expense: The company expects interest expense and interest income to offset one another.
      • Income Tax Expense: The company expects income tax expense of up to $10 million.
      • GAAP Net Loss: The company expects GAAP net loss to range from $130 million to $160 million, or a basic and diluted loss per share of $0.82 to $1.01, based on a weighted average share count of approximately 159 million shares outstanding.
      • Non-GAAP Net Income: The company expects non-GAAP net income to range from $40 million to $70 million, or a non-GAAP basic earnings per share of $0.25 to $0.44, based on a weighted average basic share count of approximately 159 million shares outstanding and a non-GAAP diluted earnings per share of $0.25 to $0.43, based on a weighted average diluted share count of approximately 161 million shares outstanding.
      • Share-Based Compensation: The company expects share-based compensation of approximately $110 million.
      • Capital Expenditures: The company expects capital expenditures to range from $45 million to $55 million.

      Conference Call

      Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. GMT) on Thursday, Feb. 13, 2020, through Thursday, Feb. 20, 2020, and may be accessed by visiting Alkermes' website or by dialing +1 877 660 6853 for U.S. callers and +1 201 612 7415 for international callers. The replay conference ID is 13698323.

      About Alkermes plc

      Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

      Non-GAAP Financial Measures

      This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

      Non-GAAP net income (loss) adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

      The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of our liquidity.

      A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

      Note Regarding Forward-Looking Statements

      Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning future financial and operating performance, business plans or prospects, including the potential cost savings that may be achieved in connection with the company's implementation of a restructuring, the company's potential to achieve profitability and long-term growth, and expectations concerning continued revenue growth from the company's commercial products and royalty streams; the potential therapeutic and commercial value of the company's marketed and development products; the FDA's target PDUFA action date for, and potential approval of, the NDA for ALKS 3831; expectations concerning future development activities, including the advancement of the ALKS 4230 clinical development program, and expansion of the company's neuroscience and oncology pipeline; and expectations concerning the company's commercial activities, including launch preparations for ALKS 3831. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and  the adequacy of the data included in our filings to support the FDA's requirements for approval of the proposed indications; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

      VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA® and ARISTADA INITIO® are registered trademarks of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson; VUMERITY® is a registered trademark of Biogen Inc., used by Alkermes under license; and AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. ("Acorda")

       (tables follow)

      _______________
      i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO, unless the context indicates otherwise.
      ii AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by Acorda and outside the U.S. by Biogen Inc., under a licensing agreement with Acorda, as FAMPYRA® (prolonged-release fampridine tablets).

      Alkermes plc and Subsidiaries







      Selected Financial Information (Unaudited)


















      Condensed Consolidated Statements of
      Operations - GAAP


      Three Months
      Ended


      Three Months
      Ended








      December 31, 


      December 31, 







      (In thousands, except per share data)


      2019


      2018







      Revenues:











      Product sales, net


      $                 149,609


      $                  132,650







      Manufacturing and royalty revenues


      107,287


      167,422







      License revenues


      144,750


      120







      Research and development revenue


      11,084


      15,570







      Total Revenues


      412,730


      315,762







      Expenses:











      Cost of goods manufactured and sold


      46,482


      49,117







      Research and development


      198,157


      108,972







      Selling, general and administrative


      154,453


      141,227







      Amortization of acquired intangible assets


      10,171


      16,426







      Restructuring expense


      13,401


      —







      Total Expenses


      422,664


      315,742







      Operating (Loss) Income


      (9,934)


      20







      Other Income (Expense), net:











      Interest income


      3,191


      3,292







      Interest expense


      (3,196)


      (3,478)







      Change in the fair value of contingent consideration


      5,000


      (2,300)







      Other income, net


      2,382


      775







      Total Other Income (Expense), net


      7,377


      (1,711)







      Loss Before Income Taxes


      (2,557)


      (1,691)







      Provision for income taxes


      2,797


      8,022







      Net Loss — GAAP


      $                    (5,354)


      $                    (9,713)


















      (Loss) Earnings Per Share:











      GAAP loss per share — basic and diluted


      $                      (0.03)


      $                      (0.06)







      Non-GAAP earnings per share — basic


      $                       0.83


      $                       0.35







      Non-GAAP earnings per share — diluted


      $                       0.83


      $                       0.34


















      Weighted Average Number of Ordinary
      Shares Outstanding:











      Basic and diluted — GAAP


      157,662


      155,506







      Basic — Non-GAAP


      157,662


      155,506







      Diluted — Non-GAAP


      159,073


      159,518


















      An itemized reconciliation between net loss on a GAAP
      basis and non-GAAP net income is as follows:











      Net Loss — GAAP


      $                    (5,354)


      $                    (9,713)







      Adjustments:











      Share-based compensation expense


      21,387


      29,314







      Amortization expense


      10,171


      16,426







      Depreciation expense


      10,340


      9,476







      Income tax effect related to reconciling items


      592


      1,533







      Non-cash net interest expense


      168


      169







      Change in the fair value of warrants and equity
      method investments


      (930)


      (410)







      Change in the fair value of contingent consideration


      (5,000)


      2,300







      Acquisition of IPR&D


      86,595


      —







      Restructuring expense


      13,401


      —







      Fixed asset impairment


      —


      5,746







      Non-GAAP Net Income


      $                  131,370


      $                    54,841






























































      Condensed Consolidated Statements of
      Operations - GAAP


      Year Ended


      Year Ended








      December 31, 


      December 31, 







      (In thousands, except per share data)


      2019


      2018







      Revenues:











      Product sales, net


      $                  524,499


      $                  450,334







      Manufacturing and royalty revenues


      447,882


      526,675







      License revenues


      145,750


      48,370







      Research and development revenue


      52,816


      68,895







      Total Revenues


      1,170,947


      1,094,274







      Expenses:











      Cost of goods manufactured and sold


      180,385


      176,420







      Research and development


      512,833


      425,406







      Selling, general and administrative


      599,449


      526,408







      Amortization of acquired intangible assets


      40,358


      65,168







      Restructuring expense


      13,401


      0







      Total Expenses


      1,346,426


      1,193,402







      Operating Loss


      (175,479)


      (99,128)







      Other Expense, net:











        Interest income


      13,976


      9,238







        Interest expense


      (13,601)


      (15,437)







        Change in the fair value of contingent consideration


      (22,800)


      (19,600)







        Other income (expense), net


      848


      (2,040)







      Total Other Expense, net


      (21,577)


      (27,839)







      Loss Before Income Taxes


      (197,056)


      (126,967)







      (Benefit) Provision for income taxes


      (436)


      12,344







      Net Loss — GAAP


      $                (196,620)


      $                (139,311)


















      (Loss) Earnings Per Share:











      GAAP net loss per share — basic and diluted


      $                      (1.25)


      $                      (0.90)







      Non-GAAP earnings per share — basic


      $                        0.71


      $                        0.63







      Non-GAAP earnings per share — diluted


      $                        0.71


      $                        0.61


















      Weighted Average Number of Ordinary
      Shares Outstanding:











      Basic and diluted — GAAP


      157,051


      155,112







      Basic — Non-GAAP


      157,051


      155,112







      Diluted — Non-GAAP


      159,056


      160,363


















      An itemized reconciliation between net loss on a GAAP
      basis and non-GAAP net income is as follows:











      Net Loss — GAAP


      $                (196,620)


      $                (139,311)







      Adjustments:











      Share-based compensation expense


      100,977


      105,357







      Amortization expense


      40,358


      65,168







      Depreciation expense


      40,055


      38,492







      Income tax effect related to reconciling items


      5,762


      (4,002)







      Non-cash net interest expense


      673


      700







      Change in the fair value of warrants and equity
      method investments


      (1,837)


      190







      Change in the fair value of contingent consideration


      22,800


      19,600







      Acquisition of IPR&D


      86,595


      —







      Restructuring expense


      13,401


      3,598







      Fixed asset impairment


      —


      5,746







      Debt refinancing charge


      —


      2,298







      Non-GAAP Net Income


      $                  112,164


      $                    97,836








































      Condensed Consolidated Balance Sheets


      December 31, 


      December 31, 







      (In thousands)


      2019


      2018







      Cash, cash equivalents and total investments


      $                  614,370


      $                  620,039







      Receivables


      257,086


      292,223







      Contract assets


      8,386


      8,230







      Inventory


      101,803


      90,196







      Prepaid expenses and other current assets


      59,716


      53,308







      Property, plant and equipment, net


      362,168


      309,987







      Intangible assets, net and goodwill


      243,516


      283,874







      Other assets


      158,358


      167,150







      Total Assets


      $               1,805,403


      $               1,825,007







      Long-term debt — current portion


      $                      2,843


      $                      2,843







      Other current liabilities


      388,269


      336,931







      Long-term debt   


      274,295


      276,465







      Contract liabilities — long-term 


      22,068


      9,525







      Other long-term liabilities


      32,486


      27,958







      Total shareholders' equity


      1,085,442


      1,171,285







      Total Liabilities and Shareholders' Equity


      $               1,805,403


      $               1,825,007


















      Ordinary shares outstanding (in thousands)


      157,779


      155,757


















      This selected financial information should be read in conjunction with the consolidated financial
      statements and notes thereto included in Alkermes plc's Annual Report on Form 10-K for the year
      ended December 31, 2019, which the company intends to file in February 2020.





























      Alkermes plc and Subsidiaries

      Revenues for Calendar Year 2019 and 2018














      Three Months


      Three Months


      Three Months


      Three Months


      Year 



      Ended


      Ended


      Ended


      Ended


      Ended



      March 31,


      June 30,


      September 30,


      December 31,


      December 31,

      (In thousands)


      2019


      2019


      2019


      2019


      2019

      Revenues:











      PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)


      $                    75,605


      $                    91,863


      $                76,716


      $                  79,147


      $             323,331

      VIVITROL


      69,183


      88,199


      85,164


      92,818


      335,364

      ARISTADA


      30,298


      48,436


      53,610


      56,791


      189,135

      Key Commercial Product Revenues


      175,086


      228,498


      215,490


      228,756


      847,830












      Legacy Product Revenues


      33,310


      36,034


      27,067


      28,140


      124,551

      License Revenue(2)


      —


      1,000


      —


      144,750


      145,750

      Research and Development Revenues


      14,706


      14,340


      12,686


      11,084


      52,816

      Total Revenues


      $                223,102


      $                279,872


      $             255,243


      $             412,730


      $          1,170,947




































      Three Months


      Three Months


      Three Months


      Three Months


      Year 



      Ended


      Ended


      Ended


      Ended


      Ended



      March 31,


      June 30,


      September 30,


      December 31,


      December 31,

      (In thousands)


      2018


      2018


      2018


      2018


      2018

      Revenues:











      PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)


      $                    68,790


      $                    85,181


      $                77,202


      $                  81,372


      $             312,545

      VIVITROL


      62,682


      76,203


      79,893


      83,831


      302,609

      ARISTADA


      29,160


      33,604


      36,142


      48,819


      147,725

      Key Commercial Product Revenues


      160,632


      194,988


      193,237


      214,022


      762,879












      Legacy Product Revenues


      45,811


      43,060


      39,209


      86,050


      214,130

      License Revenue(3)


      —


      48,250


      —


      120


      48,370

      Research and Development Revenues


      18,707


      18,344


      16,274


      15,570


      68,895

      Total Revenues


      $                225,150


      $                304,642


      $             248,720


      $             315,762


      $          1,094,274























      (1) - Includes RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA.

      (2) - Includes a milestone payment received in the fourth quarter of 2019 which was allocated to the license sold to Biogen in connection with the VUMERITY collaboration.

      (3) - Includes a milestone payment received in the second quarter of 2018 which was allocated to the license sold to Biogen in connection with the VUMERITY collaboration.























      Alkermes plc and Subsidiaries





      2020 Guidance — GAAP to Non-GAAP Adjustments
















      An itemized reconciliation between projected loss per share on a GAAP basis and projected earnings
      per share on a non-GAAP basis is as follows:









      (In millions, except per share data)


      Amount


      Shares


      (Loss) Earnings
      Per Share





      Projected Net Loss — GAAP


      $               (145.0)


      159


      $                   (0.91)





         Adjustments:











      Share-based compensation expense


      110.0









      Amortization expense


      40.0









      Depreciation expense


      44.0









      Non-cash net interest expense


      1.0









      Income tax effect related to reconciling items 


      5.0









      Projected Net Income — Non-GAAP


      $                  55.0


      161


      $                    0.34
















      Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.





      Alkermes Contacts:
      For Investors: Sandy Coombs      +1 781 609 6377
      For Media:      Eva Stroynowski   +1 781 609 6823

      Logo - http://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.